Cargando…

Development of Class IIa Bacteriocins as Therapeutic Agents

Class IIa bacteriocins have been primarily explored as natural food preservatives, but there is much interest in exploring the application of these peptides as therapeutic antimicrobial agents. Bacteriocins of this class possess antimicrobial activity against several important human pathogens. There...

Descripción completa

Detalles Bibliográficos
Autores principales: Lohans, Christopher T., Vederas, John C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236453/
https://www.ncbi.nlm.nih.gov/pubmed/22187559
http://dx.doi.org/10.1155/2012/386410
_version_ 1782218747024506880
author Lohans, Christopher T.
Vederas, John C.
author_facet Lohans, Christopher T.
Vederas, John C.
author_sort Lohans, Christopher T.
collection PubMed
description Class IIa bacteriocins have been primarily explored as natural food preservatives, but there is much interest in exploring the application of these peptides as therapeutic antimicrobial agents. Bacteriocins of this class possess antimicrobial activity against several important human pathogens. Therefore, the therapeutic development of these bacteriocins will be reviewed. Biological and chemical modifications to both stabilize and increase the potency of bacteriocins are discussed, as well as the optimization of their production and purification. The suitability of bacteriocins as pharmaceuticals is explored through determinations of cytotoxicity, effects on the natural microbiota, and in vivo efficacy in mouse models. Recent results suggest that class IIa bacteriocins show promise as a class of therapeutic agents.
format Online
Article
Text
id pubmed-3236453
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-32364532011-12-20 Development of Class IIa Bacteriocins as Therapeutic Agents Lohans, Christopher T. Vederas, John C. Int J Microbiol Review Article Class IIa bacteriocins have been primarily explored as natural food preservatives, but there is much interest in exploring the application of these peptides as therapeutic antimicrobial agents. Bacteriocins of this class possess antimicrobial activity against several important human pathogens. Therefore, the therapeutic development of these bacteriocins will be reviewed. Biological and chemical modifications to both stabilize and increase the potency of bacteriocins are discussed, as well as the optimization of their production and purification. The suitability of bacteriocins as pharmaceuticals is explored through determinations of cytotoxicity, effects on the natural microbiota, and in vivo efficacy in mouse models. Recent results suggest that class IIa bacteriocins show promise as a class of therapeutic agents. Hindawi Publishing Corporation 2012 2011-11-30 /pmc/articles/PMC3236453/ /pubmed/22187559 http://dx.doi.org/10.1155/2012/386410 Text en Copyright © 2012 C. T. Lohans and J. C. Vederas. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Lohans, Christopher T.
Vederas, John C.
Development of Class IIa Bacteriocins as Therapeutic Agents
title Development of Class IIa Bacteriocins as Therapeutic Agents
title_full Development of Class IIa Bacteriocins as Therapeutic Agents
title_fullStr Development of Class IIa Bacteriocins as Therapeutic Agents
title_full_unstemmed Development of Class IIa Bacteriocins as Therapeutic Agents
title_short Development of Class IIa Bacteriocins as Therapeutic Agents
title_sort development of class iia bacteriocins as therapeutic agents
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236453/
https://www.ncbi.nlm.nih.gov/pubmed/22187559
http://dx.doi.org/10.1155/2012/386410
work_keys_str_mv AT lohanschristophert developmentofclassiiabacteriocinsastherapeuticagents
AT vederasjohnc developmentofclassiiabacteriocinsastherapeuticagents